Savara

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Savara and other ETFs, options, and stocks.

About SVRA

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. 

CEO
Matthew Pauls
CEOMatthew Pauls
Employees
59
Employees59
Headquarters
Langhorne, Pennsylvania
HeadquartersLanghorne, Pennsylvania
Founded
1995
Founded1995
Employees
59
Employees59

SVRA Key Statistics

Market cap
1.12B
Market cap1.12B
Price-Earnings ratio
-10.26
Price-Earnings ratio-10.26
Dividend yield
Dividend yield
Average volume
1.63M
Average volume1.63M
High today
$5.66
High today$5.66
Low today
$5.43
Low today$5.43
Open price
$5.57
Open price$5.57
Volume
1.26M
Volume1.26M
52 Week high
$7.01
52 Week high$7.01
52 Week low
$1.89
52 Week low$1.89

Stock Snapshot

Savara(SVRA) stock is priced at $5.49, giving the company a market capitalization of 1.12B. It carries a P/E multiple of -10.26.

On 2026-03-05, Savara(SVRA) stock moved within a range of $5.43 to $5.66. With shares now at $5.49, the stock is trading +1.2% above its intraday low and -2.9% below the session's peak.

Trading volume for Savara(SVRA) stock has reached 1.26M, versus its average volume of 1.63M.

The stock's 52-week range extends from a low of $1.89 to a high of $7.01.

The stock's 52-week range extends from a low of $1.89 to a high of $7.01.

SVRA News

Simply Wall St 3d
Why Savara Is Up 5.4% After FDA Grants Priority Review To MOLBREEVI Application

Savara Inc. recently announced that the FDA has accepted for review its Biologics License Application for MOLBREEVI to treat autoimmune pulmonary alveolar prote...

Why Savara Is Up 5.4% After FDA Grants Priority Review To MOLBREEVI Application
Simply Wall St 6d
Assessing Savara Valuation After FDA Priority Review For MOLBREEVI

Savara (SVRA) is back in focus after the FDA accepted for review the biologics license application for MOLBREEVI to treat autoimmune pulmonary alveolar proteino...

Assessing Savara Valuation After FDA Priority Review For MOLBREEVI

Analyst ratings

100%

of 8 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own SVRA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.